A single center's experience of the extrapulmonary neuroendocrine carcinomas

Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC. This retrospective...

Full description

Saved in:
Bibliographic Details
Published inNorthern Clinics of Istanbul Vol. 9; no. 1; pp. 35 - 40
Main Authors Celik, Emir, Samanci, Nilay Sengul, Derin, Sumeyra, Bedir, Sahin, Degerli, Ezgi, Oruc, Kerem, Oztas, Nihan Senturk, Alkan, Gulin, Senyigit, Abdulhalim, Turna, Zeynep Hande
Format Journal Article
LanguageEnglish
Published Turkey KARE Publishing 2022
Kare Publishing
Health Directorate of Istanbul
Subjects
Cancer
Care and treatment
Chemotherapy
Combination therapy
Development and progression
Etoposide
Health aspects
Liver
Medical records
Medical research
Medicine, Experimental
Metastasis
Original - Medical Oncology
Patients
platinum and etoposide
Extrapulmonary neuroendocrine carcinoma
liver metastasis
Online AccessGet full text

Cover

More Information
Summary:Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC. This retrospective study was conducted based on the medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC. Forty-seven patients were included in the study. About 72.3% (n=34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide, was 5.83 months (95% CI 4.46-7.20), whereas the median OS of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01-18.18). There was no difference in PFS and OS between patients with and without liver metastasis. The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Cite this article as: Celik E, Samanci NS, Derin S, Bedir S, Degerli E, Oruc K, et al. A single center’s experience of the extrapulmonary neuroendocrine carcinomas. North Clin Istanb 2022;9(1):35–40.
ISSN:2148-4902
2149-4902
2536-4553
DOI:10.14744/nci.2021.47887